Key facts
- It has raised $3.9M; the latest was Seed Round ($3.1M) in Jan 2025.
- Notable investors include InnovationQuarter, Massachusetts Institute of Technology Endowment, INNOWIDE, Libertatis Ergo Holding (LEH), LifeSciences@Work — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for BIMINI Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for BIMINI Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BIMINI Biotech
Developer of small-molecule therapeutics designed for targeted modulation of the protein for oncology and autoimmune research. The company specializes in the research and development of oncology medicines that render the growth hormone receptor dysfunctional, making the cells less sensitive to growth hormone, as seen in the syndrome, enabling healthcare researchers and biopharmaceutical developers to pursue more precise therapeutic strategies for complex malignancies and immune-driven disorders.
- Sector
- Healthcare
- HQ
- Leiden, Netherlands
- Founded
- 2019
- Employees
- 9
- Website
- biminibiotech.nl/
- Ownership
- Privately Held (backing)
BIMINI Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BIMINI Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BIMINI Biotech in its N-PORT filings yet. We sweep new filings monthly.